 NEW YORK LONDON PARIS--BUSINESS WIRE-- biopharmaceutical--Aptorum Group Limited Nasdaq: APM, Euronext Paris: APM Aptorum Group or Aptorum, a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, announced that the company, through its wholly owned subsidiary, Aptorum International Limited, has received clearance from the Public Health Agency of Canada Health Canada regarding the Clinical Trial Application CTA to commence a Phase 1 study of ALS-4 